Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients

QR Code

Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients

Ngamkae Ruangvaravate, Karnthida Choojun, Benjawan Srikulsasitorn, Jatupol Chokboonpiem, Dechathon Asanatong, Supaporn Trakanwitthayarak Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandCorrespondence: Ngamkae RuangvaravateDepartment of Ophthalm...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Ruangvaravate N, Choojun K, Srikulsasitorn B, Chokboonpiem J, Asanatong D, Trakanwitthayarak S
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2020
Sujets:	glaucoma ocular surface disease preservative-free tafluprost tear break up time Ophthalmology RE1-994
Accès en ligne:	https://doaj.org/article/3f4d43cba7d24a148f7bc2859b2d5c55
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study
par: Pillunat LE, et autres
Publié: (2017)

The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study
par: Okumichi H, et autres
Publié: (2017)

Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials
par: Uusitalo H, et autres
Publié: (2016)

Switching from concomitant therapy to tafluprost/timolol fixed combination
par: Inoue K, et autres
Publié: (2018)

Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments
par: Stalmans I, et autres
Publié: (2020)

Efficacy and safety of tafluprost 0.0015% – retrospective analysis of real-world data from the Philippines
par: Tumbocon JA, et autres
Publié: (2019)

The 24-hour intraocular pressure control by tafluprost/timolol fixed combination after switching from the concomitant use of tafluprost and timolol gel-forming solution, in patients with primary open-angle glaucoma
par: Nakamoto K, et autres
Publié: (2018)

Keratograph 5M As A Useful And Objective Tool For Evaluating The Ocular Surface In Limbal Stem Cell Deficiency
par: Alfaro-Juárez A, et autres
Publié: (2019)

Glaucoma therapy: preservative-free for all?
par: Thygesen J
Publié: (2018)

An assessment of the ocular tear film in patients with thyroid disorders
par: Alanazi SA, et autres
Publié: (2019)

Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
par: Erb C, et autres
Publié: (2021)

Efficacy and Safety of VisuEvo® and Cationorm® for the Treatment of Evaporative and Non-Evaporative Dry Eye Disease: A Multicenter, Double-Blind, Cross-Over, Randomized Clinical Trial
par: Fogagnolo P, et autres
Publié: (2020)

Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost
par: Hommer A, et autres
Publié: (2011)

Impact of Ocular Surface Disease Treatment in Patients with Glaucoma
par: Mylla Boso AL, et autres
Publié: (2020)

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction
par: Muñoz Negrete FJ, et autres
Publié: (2017)

Effects of short-term oral vitamin A supplementation on the ocular tear film in patients with dry eye
par: Alanazi SA, et autres
Publié: (2019)

Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension
par: Lanzl I, et autres
Publié: (2013)

Influence on ocular surface after cataract surgery and effect of topical diquafosol on postoperative dry eye: a multicenter prospective randomized study
par: Miyake K, et autres
Publié: (2017)

Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial
par: Tauber J, et autres
Publié: (2020)

Agreement of non-invasive tear break up time measurement between Tomey RT-7000 Auto Refractor-Keratometer and Oculus Keratograph 5M
par: Lee R, et autres
Publié: (2016)

Risk factors for ocular surface damage in Mexican patients with dry eye disease: a population-based study
par: Rodriguez-Garcia A, et autres
Publié: (2018)

Real-life results of switching from preserved to preservative-free artificial tears containing hyaluronate in patients with dry eye disease
par: Nasser L, et autres
Publié: (2018)

Improved Tear Film Stability in Patients with Dry Eye After Hyaluronic Acid and Galactoxyloglucan Use
par: Molina-Solana P, et autres
Publié: (2020)

Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study
par: Economou MA, et autres
Publié: (2018)

Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
par: Ermiş&nbsp;SS
Publié: (2012)

The proportion of ocular surface diseases in untreated patients with epiphora
par: Ishikawa S, et autres
Publié: (2018)

Ocular hypotensive effects of prostaglandin analogs in Japanese patients with normal-tension glaucoma: a literature review
par: Takagi Y, et autres
Publié: (2018)

Possible association between subtypes of dry eye disease and seasonal variation
par: Ayaki M, et autres
Publié: (2017)

Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma
par: Ikeda Y, et autres
Publié: (2016)

Ocular lubricant use in medically and surgically treated glaucoma: a retrospective longitudinal analysis
par: Iyer JV, et autres
Publié: (2017)

Efficacy and tolerability of preservative-free tafluprost 0.0015% in Korean patients with glaucoma
par: Hwang YH
Publié: (2013)

Prospective, non-interventional, multicenter study of the intraocular pressure-lowering effects of prostaglandin analog/prostamide-containing therapies in previously treated patients with open-angle glaucoma or ocular hypertension
par: Tamçelik N, et autres
Publié: (2017)

Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost
par: Sacchi M, et autres
Publié: (2014)

Blood pressure, ocular perfusion pressure and open-angle glaucoma in patients with systemic hypertension
par: Cantor E, et autres
Publié: (2018)

Intraocular pressure 1 year after vitrectomy in eyes without a history of glaucoma or ocular hypertension
par: Fang Y, et autres
Publié: (2017)

Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
par: Dorota Pozarowska
Publié: (2010)

Cytokine biomarkers in tear film for primary open-angle glaucoma
par: Gupta D, et autres
Publié: (2017)

A Retrospective Data Review Confirms That Topical Preservative-Free Hydrocortisone Improves Inflammation in Dry Eye Disease
par: Kuzmanović Elabjer B, et autres
Publié: (2020)

The clinical effectiveness of tafluprost on Japanese normal-tension glaucoma patients
par: Nomura A, et autres
Publié: (2018)

Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension
par: Makoto Aihara
Publié: (2010)